Fruquintinib, sold under the brand name Fruzaqla, is an oral medication used to treat adults with metastatic colorectal cancer (mCRC) who have previously undergone other treatments
. It works by inhibiting vascular endothelial growth factor receptors (VEGFRs), which helps block the formation of new blood vessels that tumors need to grow
It was approved for medical use in the United States in November 20232
. However, it can cause side effects like high blood pressure, hand-foot syndrome, and gastrointestinal issues
Fruquintinib, marketed as Fruzaqla, is approved in several countries.
As of now, it's available in the United States, European Union, Japan, mainland China, Hong Kong, and Macau
Fruquintinib has been well-received globally
. In the United States, it was approved by the FDA in November 20231
. The European Union followed with approval in June 2024, marking a significant milestone as the first novel targeted therapy for metastatic colorectal cancer in over a decade2
. Japan also approved fruquintinib in September 20243
The global Phase 3 FRESCO-2 trial played a crucial role in these approvals, demonstrating significant improvements in overall survival and progression-free survival for patients2
. It's exciting to see such a promising treatment becoming more widely available!
You can also consult us: @RxLibra
¿Dónde comprar Aumolertinib?Где купить аумолертиниб（Aumolertinib）?ซื้อ Aumolertinib ได้ที่ไหน?Where to Buy Aumolertinib？
¿Dónde comprar Furmonertinib?
Copyright © 2021-2022 LienTeh.net All rights reserved.
